Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights. "We have made significant progress this year across all our programs and are very excited for the upcoming readout of our Phase 3 clinical trial of pegzilarginase in Arginase 1 Deficiency," said Anthony Quinn, M.B.

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that seven abstracts will be presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) 2021 being held November 21-23, 2021. The series of abstracts illustrate the building interest and knowledge around the clinical impact of Arginase 1 Deficiency (ARG1-D), the importance of increased disease awareness to drive more rapid and accurate diagnosis and the need for improved treatments given the significant limitations of the current standard of care.

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics

AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences:  Investor Meetings 2021 Wells Fargo Virtual Healthcare Conference, September 9 H.C.

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights. "2021 is proving to be a pivotal year for Aeglea.

Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, July 15, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jim Kastenmayer, Ph.D., J.D., as general counsel.

Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a rare, progressive and devastating disease characterized by high levels of the amino acid arginine. Pegzilarginase is a novel, recombinant human arginase 1 enzyme designed to lower levels of arginine that is also being investigated in PEACE, an ongoing Phase 3 pivotal trial for the treatment of ARG1-D.

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jonathan D. Alspaugh as Chief Financial Officer.

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer

AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the dosing of the first patient in the Company's first-in-human Phase 1/2 clinical trial investigating AGLE-177 for the treatment of Homocystinuria. The markedly elevated plasma homocysteine levels lead to a wide range of life-altering complications and reduced life expectancy in people with Homocystinuria.

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria

AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. (NASDAQ: PRAX).

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea's pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily metabolic enzyme-related indications including arginase 1 deficiency, the indication of its lead Phase 3 therapeutic, Pegzilarginase.

Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial results, and provided recent corporate and program highlights. "We've had a strong start to 2021 and I am excited to see the significant momentum we have built for our pegzilarginase program from a clinical perspective as well as strengthening our commercial foundation in preparation for a potential FDA approval and launch.

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease education initiative focused on improving the awareness and diagnosis of Arginase 1 Deficiency (ARG1–D), a devastating and progressive rare metabolic disease. People living with ARG1-D are faced with debilitating, progressive disease manifestations that create significant challenges in daily life, including mobility issues, intellectual disability, developmental delays and seizures.

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency

AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has completed patient randomization for PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). ARG1-D is a rare, progressive disease characterized by high levels of arginine which results in severe mobility limitations due to spasticity, seizures, developmental delay, intellectual disability and early mortality.

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency

AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021.   Conference Details Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access DayConference Date: Tuesday, April 6 and Thursday, April 8 Participants: Anthony G.

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a novel, recombinant human arginase 1 enzyme that has been shown to lower toxic levels of the amino acid arginine in patients with Arginase 1 Deficiency (ARG1-D). People living with ARG1-D, a rare, progressive disease characterized by high levels of arginine, may experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability and early mortality.

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its fourth quarter and full year 2020 financial results, and provided recent corporate and program highlights. "2020 was a challenging year advancing our clinical trials and at the same time prioritizing the health and well-being of the rare disease patients we serve, who often have additional difficulties and vulnerabilities," said Anthony Quinn, M.B Ch.B, Ph.D.

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Sara Brownstein...

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial...

Aeglea BioTherapeutics Announces Transition of Chief Financial Officer

AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will present at the 39th Annual J.P....

Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aeglea (AGLE) Upgraded to Buy: Here's Why

AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of...

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug...

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its...

News for Aeglea BioTherapeutics Stock (AGLE)